Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
"There was a significant increase in overall fatigue after performing flexible ureteroscopy," says Sarah Razavi, MD.
Study results affirm effectiveness of evolving prostate cancer therapies
“I think it does give us confidence that clinical trials can predict how these drugs will work in the real world," says Stephen J. Freedland, MD.
Yahir A. Santiago-Lastra, MD, discusses barriers to vaginal estrogen access
"The black box warning affects that ability for them to get access to that critical drug, vaginal estrogen," says Yahir A. Santiago-Lastra, MD.
Expert discusses genitourinary syndrome of menopause guidelines
Among the guideline’s recommendations is the use of local low-dose vaginal estrogen as first-line therapy for GSM.
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
The study was published in JCO Oncology Practice.
Investigators evaluate patient outcomes with silicone vs polyurethane stents
John Michael DiBianco, MD, discusses findings from the BLUES trial.
Durvalumab plus BCG significantly improves DFS in NMIBC
The data are to be presented at an upcoming medical conference.
Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
Investigators found that benefits of treatments that are observed in trials also appear in the real world.
Expert discusses the NMIBC trials landscape
"It’s a very good time to be taking care of patients with bladder cancer," says Joshua J. Meeks, MD, PhD.
Experts discuss expanding use of vibegron for OAB
Grace Khaner and Melissa A. Laudano, MD, share their thoughts on the potential for expanding the use of vibegron early in treatment for OAB.
AUA Advocacy Summit: Medicare payment reform among top priorities
Jennifer Miles-Thomas, MD, URPS, MBA, discusses the AUA's legislative priorities along with issues in medicine related to artificial intelligence.
John Michael DiBianco, MD, on silicone vs polyurethane stents for patients with kidney stones
DiBianco discusses findings from the Better Lithotripsy and Ureteroscopy Evaluation of Stenting trial.
Health policy expert highlights the importance of state-level urology advocacy
"Developing a relationship with your legislator is just as important at the state level as it is at the federal level," says Hans Arora, MD, PhD.
Karyn S. Eilber, MD, shares her reaction to genitourinary syndrome of menopause guidelines
“I think the best thing about these guidelines is their actual existence,” says Karyn S. Eilber, MD.
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
"To me, the key take-home is that the benefits that we see in clinical trials, we actually can replicate in the real world," says Stephen J. Freedland, MD.
Endourologist discusses shared decision-making and laser lithotripsy
Safety, efficacy of vibegron sustained in men with OAB treated for BPH
The investigators reported an overall incidence of AEs of 29.6%.
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
“It's going to be an important time for US urologists to identify that this is becoming the standard of care," says Joshua J. Meeks, MD, PhD.
Ultra-low PSA responses are more prevalent with darolutamide plus ADT
The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
Cxbladder Triage may help patients avoid unnecessary cystoscopies
The study population was able to avoid 952 cystoscopies and 70 CT scans, according to the investigators.
Investigational ProVee System impresses in phase 3 trial in BPH
No device- or procedure-related serious AEs were observed through 12 months across the entire study population
ARANOTE substudy highlights benefits of darolutamide in Black men
The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
CVAC 2.0 demonstrates efficacy for clearing stones less than 2 cm
The investigators reported a median stone clearance of 96.44%.
Nogapendekin alfa inbakicept shows high CR, avoidance of cystectomy in NMIBC
In cohort A, the cystectomy-free rate at 36 months was 84%.
Most men in EMBARK trial recover T levels following treatment suspension
More than 80% of patients in both groups had a full recovery of testosterone.
UGN-102 positions itself as an alternative to TURBT for low-grade NMIBC
"I would argue that UGN-102 may very well represent a well-tolerated alternative to TURBT as primary treatment for patients with low-grade disease,” says Sandip M. Prasad, MD, MPhil.
Estimated DOR of 2 years is seen with UGN-102 in LG-IR-NMIBC
The investigators reported that the median Kaplan-Meier estimate of DOR was 24.2 months.
Cretostimogene yields high CR rate in BCG-unresponsive NMIBC
"97% [of patients] remain progression free, and 84.5% avoided cystectomy, highlighting cretostimogene’s bladder-sparing potential,” said Mark D. Tyson II, MD, MPH.
CREST: Significant EFS boost seen with sasanlimab plus BCG in NMIBC
“In the patients with CIS, the probability of a continued complete response at 36 months was 92% vs 67.7%," said Neal D. Shore, MD, FACS.
ADVANCED-002: High CR rates observed with TARA-002 in high-grade NMIBC
Treatment with TARA-002 was associated with a 100% high-grade CR at any time in BCG-unresponsive participants.
Study shows value of precision-based approaches in prostate cancer
Urologic surgeons successfully complete world’s first bladder transplant
Patient selection for cytoreductive nephrectomy in 2025
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD